Class of Stock [Axis] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total stockholders defici attributable to zeo [Member] Noncontrolling Interest [Member] Customer [Axis] Large distributor [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Another large distributor [Member] Large medical pactice group [Member] Accounts Receivable [Member] Customer one [Member] One supplier [Member] Two supplier [Member] Antidilutive Securities [Axis] Common shares issuable upon the exercise of options and warrants [Member] Common shares issuable upon the exercise of unissued restricted stock [Member] Common shares issuable upon the exercise of unvested shares of restricted stock [Member] Convertible Debt Securities [Member] Common shares issuable upon the future payments [Member] Long-Lived Asset, Class [Axis] Finance lease equipment [Member] Manufacturing Equipment [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Sales representative agreement [Member] Lease Agreement [Member] Related and Nonrelated Parties [Axis] Serephon [Member] Counterparty Name [Axis] Ian Bothwell [Member] Dr. George Shapiro [Member] Greyt Ventures LLC [Member] Long-Term Debt, Type [Axis] Convertible promissory notes [Member] 4 Investors [Member] Award Type [Axis] Warrant [Member] Holder [Member] Series C Non-Convertible Preferred Stock [Member] Title and Position [Axis] Investor [Member] Fifteen Investors [Member] Eight Investors [Member] Plan Name [Axis] 2021 Plan [Member] Sales distribution agreement [Member] Salesco [Member] Twenty individuals [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Restricted Stock Awards [Member] Consulting Agreement [Member] Consultant [Member] Second Consultant [Member] Business Combination [Axis] BioLumina, LLC [Member] 2021 Incentive Stock Plan [Member] Employee [Member] 2021 Plan [Member] Chief Executive Officer [Member] Chief Medical Officer [Member] Employment Agreement [Member] Dr. Kisiday [Member] Unvested stock grants [Member] Unvested shares [Member] Equity Option [Member] Director [Member] Dr. Leider [Member] Dr. Howard Golub [Member] Dr. Everts [Member] Employees, officers and directors [Member] Employees [Member] Options Vesting [Member] Options Outstanding [Member] Two Consultants [Member] Third party [Member] Consultants [Member] 4 Tranches [Member] Dr. George Shapiro [Member] Monte Carlo Simulation [Member] Monte carlo [Member] Supply agreement [Member] Settlement agreement [Member] Howard Golub [Member] Legal Entity [Axis] Management Services Organization [Member] Related Parties [Member] Zeo Shares [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Individual [Axis] Ian T Bothwell [Member] Ian T Bothwell Member 1 [Member] Ian T Bothwell Member 2 [Member] Ian T Bothwell Member 3 [Member] Ian T Bothwell Member 4 [Member] Ian T Bothwell Member 5 [Member] Dr George Shapiro 1 [Member] Dr George Shapiro 2 [Member] Dr George Shapiro 3 [Member] Dr George Shapiro 4 [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Accounts receivable, net of allowance for bad debts Prepaid expenses Inventories Total Current Assets Property and equipment, net Security deposits TOTAL ASSETS LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued expenses Finance lease obligations Convertible promissory note, net of debt discount of $2,000 and $7,000 Obligation to repurchase shares Deferred revenue Share-based compensation liability to related parties Total Current Liabilities Long term finance lease obligations Total Liabilities Commitments and contingencies Shares Subject To Possible Redemption Preferred stock value Stockholders’ Equity (Deficit) Common stock, $0.001 par value, 2,500,000,000 shares authorized; 7,837,441 and 6,747,441 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total equity (deficit) attributable to Zeo ScientifiX, Inc. Non-controlling interests Total Stockholders’ Equity (Deficit) TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT) Debt discount Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues (includes sales to related parties of approximately $70,000, $88,000 and $199,000, respectively) Cost of revenues Gross profit General and administrative expenses (Including $4,697,000, $4,091,000 and $3,445,000 of stock based compensation to related parties) Loss from operations Other income (expense) Gain on Sale of Exotropin interests Interest expense Change in obligation to repurchase shares Inducement expense to convert Notes payable Impairment of non-marketable securities in a related entity Other income Net loss Net income attributable to the non-controlling interests Net loss attributable to Zeo ScientifiX, Inc. Net loss per common share - basic Net loss per common share - diluted Weighted average number of common shares outstanding - basic Weighted average number of common shares outstanding - diluted Sales to related parties Stock based compensation to related parties Beginning balance, value Beginning balance, shares Sale of common stock Sale of common stock, shares Inducement expense to convert Notes payable Conversion of Notes payable Conversion of Notes payable, shares Acquisition of BioLumina Acquisition of BioLumina, shares Exercise of warrants Exercise of warrants, shares Reverse split round-up adjustment Reverse split round-up adjustment, shares Cancellation of shares in connection with litigation Cancellation of shares in connection with litigation, shares Purchase of shares in connection with litigation Purchase of shares in connection with litigation, shares Exchange of accounts payable for stock Exchange of accounts payable for stock, shares Fair value of equity instruments issued for compensation: Fair value of shares issued Fair value of shares issued, shares Fair value of options issued Fair value of warrants issued Net (loss) income Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense Amortization of debt discount – Promissory notes Gain on sale of Exotropin interests Change in obligation to repurchase shares Inducement expense to convert Notes Reserve of non-marketable securities – related party Write-off of advances payable to former officer Stock-based compensation Amortization of share-based compensation liability Bad debt expense Changes in operating assets and liabilities: Accounts receivable, net of allowance for bad debts Other receivables Prepaid expenses Inventories Accounts payable and accrued expenses Security deposits Deferred revenue Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of fixed assets Investment in Exotropin interests - related party Proceeds from sale of Exotropin interests - related party Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES Payments on finance leases Shares repurchased in connection with litigation Proceeds from exercise of warrants Proceeds from sale of common stock Net cash provided by financing activities Increase (decrease) in cash Cash at beginning of period Cash at end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for taxes Cash paid for interest NON-CASH INVESTING AND FINANCING TRANSACTIONS: Reduction in royalty payable through transfer of inventory Reduction in liability from sale of Exotropin interests Finance lease obligations Stock issued – Purchase of BioLumina assets Conversion of notes payable and accrued interest for equity Royalty payable in connection with purchase of BioLumina assets Obligation to repurchase shares in connection with purchase of BioLumina assets Reduction in accounts payable for equipment returned to vendor Exchange of shares for payables Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES GOING CONCERN Inventory Disclosure [Abstract] INVENTORIES Property, Plant, and Equipment [Abstract] PROPERTY AND EQUIPMENT Equity In Non-marketable Securities Of Affiliated Entity EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY Finance Lease Obligations FINANCE LEASE OBLIGATIONS Variable Interest Entity With Related Party VARIABLE INTEREST ENTITY WITH RELATED PARTY Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Debt Disclosure [Abstract] NOTES PAYABLE Income Tax Disclosure [Abstract] INCOME TAXES Equity [Abstract] CAPITAL STOCK Stock Options And Warrants STOCK OPTIONS AND WARRANTS SHARE-BASED COMPENSATION LIABILITY TO RELATED PARTIES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Other Income and Expenses [Abstract] OTHER INCOME Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] ACQUISITION OF BIOLUMINA ASSETS SEGMENT INFORMATION Unaudited Comparative Financial Information UNAUDITED COMPARATIVE FINANCIAL INFORMATION Subsequent Events [Abstract] SUBSEQUENT EVENTS Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Terminated [Flag] Awards Close in Time to MNPI Disclosures [Table] Awards Close in Time to MNPI Disclosures [Table Text Block] Awards Close in Time to MNPI Disclosures, Individual Name Award Underlying Securities Amount Award Exercise Price Basis of Presentation Concentrations of Risk Use of Estimates Cash Equivalents Accounts Receivable Inventory Property and Equipment Leasehold Improvements Revenue Recognition Net Income (Loss) Per Common Share Stock-Based Compensation Research and Development Costs Income Taxes Fair Value of Financial Instruments Operating Lease Obligations Subsequent Events Recently Issued Accounting Pronouncements Schedule of inventories Schedule of property and equipment Schedule of equity in non marketable securities Schedule of minimum lease payment to finance lease Schedule of account payable and accrued expenses Schedule of notes payable Schedule of provision for income tax Schedule of effective income tax rate Schedule of deferred tax assets and liabilities Schedule of non vested share activity Schedule of stock options and warrants Schedule of assumptions used for the options granted Schedule of option pricing model Schedule of granting option pricing model Schedule of warrant activity Schedule of Black-Scholes option pricing model Schedule of roll-forward of the share based compensation Schedule of deferred revenue Schedule of other Income Schedule of significant segment expenses Schedule of Unaudited consolidated Statements Of Operation Reverse stock split Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] FDIC limits per institutions Cash balances Revenues Concentration percentage Raw material Antidilutive securities excluded from computation of earnings per share Operating and finance lease obligation Net loss Cash from operating activities Raw materials and supplies Finished goods Total inventories Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Line Items] Property and equipment, gross Less: accumulated depreciation Total property and equipment, net Depreciation expense Equity in non-marketable securities Reserve on carrying value of investment in non-marketable securities Equity in non-marketable securities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Aggregate cash consideration description Gain from sale of Exotropin interests Proceeds from sale of interests in Exotropin Reduction of previously recorded liabilities Commissions 2027 2028 2029 2030 2031 Thereafter Total undiscounted finance lease payments Less: imputed interest Present value of finance lease liabilities Payment to acquire Monthly payments Annual interest rate Estimated useful lives of leased equipment Finance lease obligations Finance lease obligations current Finance lease obligations current Weighted average remaining term of finance leases Rent expense Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Annual compensation Cumulative revenues Recognized revenues Net profit Total assets Total liabilities Accrued payroll related liabilities Lab equipment and supplies payables Clinical trial and research payables Legal fees payable Other professional fees payable Interest payable Royalty payable Accrued commissions payable Construction payables Accrued Serephon compensation Other payables and accrued expenses Total Accounts Payable and Accrued Expenses Convertible Promissory Notes Unamortized discount Total Notes Payable Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Due date Interest rate Trading days Conversion price Share price Principal amount Inducement expense Discount Debt amortized discount Debt discount Remaining outstanding Number of shares converted Interest paid Current: Federal State Current Income Tax Expense (Benefit) Deferred: Federal State Deferred Income Tax Expense (Benefit) Change in Valuation Allowance Income tax provision  Tax at federal statutory rate State taxes, net of federal benefit Permanent differences Stock-based compensation Other Total income tax expense (benefit) Change in valuation allowance Deferred Tax Assets: Stock based compensation Net operating loss carryforward-Federal Net operating loss carryforward-State Other Total deferred tax assets: Deferred Tax Liabilities: Property and equipment Total deferred tax liabilities: Valuation Allowance Net deferred tax assets Statutory income tax rate Penalties Number of nonvested shares outstanding at beginning Fair value of nonvested shares outstanding at beginning Weighted- average grant date value, outstanding at beginning Non-vested shares granted Fair value of non-vested shares granted Weighted- average grant date value, non-vested shares granted Vested Fair value of vested shares Weighted- average grant date value, vested Expired/forfeited Fair value of expired/forfeited shares Weighted- average grant date value, expired/forfeited Number of nonvested shares, outstanding at end Fair value of nonvested shares, outstanding at end Weighted- average grant date value, outstanding at end Stock, Class of Stock [Table] Class of Stock [Line Items] Shares issued Warrant to purchase Subscription agreement description Number of units sold Aggregate purchase price Shares description Number of warrants purchased Maximum aggregate number of shares Number of shares, outstanding Future issuance Legal fees payable Stock issued in exchange of legal fees payable, shares Stock issued in exchange of legal fees payable Monthly advance Shares granted Vesting period Cumulative sales from customers Stock-based compensation expense Share Price Value of shares issued Description incentive plan Grant of unvested restricted common stock Fair value of the shares as of the date of grant Grant of unvested restricted common stock description Number of restricted shares acquired Value of restricted shares acquired Number of shares awarded Forfeited in period Option vested Shares issued Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of shares, outstanding beginning balance Weighted-average exercise price, outstanding beginning balance Remaining contractual term (years), outstanding beginning balance Aggregate intrinsic value, outstanding beginning balance Number of shares, granted Weighted-average exercise price, granted Remaining contractual term (years), granted Aggregate intrinsic value, granted Number of shares, exercised Weighted-average exercise price, exercised Aggregate intrinsic value, exercised Number of shares, expired/forfeited Weighted-average exercise price, expired/forfeited Remaining contractual term (years), expired/forfeited Aggregate intrinsic value, expired/forfeited Number of shares outstanding ending balance Weighted-average exercise price outstanding ending balance Aggregate intrinsic value outstanding ending balance Number of shares, exercisable Weighted-average exercise price, exercisable Remaining contractual term (years) outstanding, exercisable Aggregate intrinsic value, exercisable Exercise prices Expected dividends Expected volatility Risk free interest rate Expected life of options Remaining contractual term (years), outstanding Aggregate intrinsic value outstanding beginning balance Number of shares, exercised Remaining contractual term (years), granted, exercised Aggregate intrinsic value outstanding ending balance Remaining contractual term (years), exercisable Vesting period Option grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Number of shares issued Exercise price Term Warrants exercisable period Expected stock volatility Expected dividend rate Fair value of warrants granted Unamortized compensation costs Purchased of warrants Exercisable for a period Exercise price Warrants description Compensation liability, beginning balance Stock based compensation expense Compensation liability, ending balance Options granted Options exercise price Compensation expense related Advances On Future Purchases Of Inventory Sales To Customers Not Yet Delivered Total Deferred Revenue Base salary for first year Outstanding advances Gain, net of obligations in connection with termination of supply agreement (see Note 14) Shares repurchased, shares Shares repurchased, value Settlement expenses Proceed from sale of products Commissions Advances payable Compensation expense related Other income Gain on write-off of advances payable to former officer and settlement on outstanding payables (see Note 16) Gain, net of obligations in connection with termination of supply agreement (see Note 15) Gain on sale of Exotropin interests Resolution and settlement of long outstanding payables Commissions on sales of Exotropin products Proceeds from insurance claim Other Total Business Combination [Table] Business Combination [Line Items] Purchase price Additional obligation Revenue Cost of revenues Salaries & consulting fees Professional fees Stock-based compensation Lab expenses Research & development Marketing Office expenses & other Other income (expenses), net Gross profit General and administrative expenses Loss from operations Net loss attributable to Zeo ScientifiX, Inc Subsequent Event [Table] Subsequent Event [Line Items] Accrued interest Manufacturing Equipment [Member] 2021 Plan [Member] [Default Label] Dr.GeorgeShapiroMember Assets, Current Liabilities, Current Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Income (Loss) Interest Expense, Operating and Nonoperating InducementExpenseToConvertNotesInPayable ImpairmentOfNonmarketableSecuritiesInRelatedEntity Shares, Outstanding WriteoffOfAdvancesPayableToFormerOfficer Increase (Decrease) in Accounts Receivable Increase (Decrease) in Other Receivables Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Security Deposits IncreaseDecreaseInDeferredRevenues Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Property, Plant, and Equipment InvestmentInNonmarketableEquitySecuritiesRelatedParty Cash Provided by (Used in) Investing Activity, Including Discontinued Operation PaymentsOnFinanceLeases SharesRepurchasedInConnectionWithLitigation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Notes Assumed Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Marketable Securities, Noncurrent Finance Lease, Liability, to be Paid Finance Lease, Liability, Undiscounted Excess Amount FinanceLeaseObligations Debt Instrument, Unamortized Discount, Current Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Income Tax Expense (Benefit) StockbasedCompensation TotalIncomeTaxExpenseBenefit Deferred Tax Assets, Other Deferred Tax Assets, Gross Deferred Tax Liabilities, Net Deferred Tax Assets, Valuation Allowance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares FairValueOfNonvestedShares Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price FairValueOfVestedShares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period FairValueOfExpiredforfeitedShares Legal Fees Shares, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding VestingPeriod Class of Warrant or Right, Exercise Price of Warrants or Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCompensationLiabilityValue Payments for Commissions CompensationExpenseRelated Other Income Other Nonoperating Income (Expense) Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Professional Fees Employee Benefit and Share-Based Payment Arrangement, Noncash Labor and Related Expense Research and Development Expense Marketing Expense Salary and Wage, Officer, Excluding Cost of Good and Service Sold